Spotlight On... Stryker could aim for enhanced damages in Zimmer Biomet patent case; Patients who intensively control diabetes cut their risk of diabetic retinopathy; and more...

Johnson & Johnson Innovation – JJDC joined as a new corporate investor in the fourth Gilde Healthcare fund. Another strategic investor, Royal Philips ($PHG), was a cornerstone investor in the new fund; it had invested in the firm's prior fund as well. The €250 million ($285 million) later stage and growth capital fund will be invested in private companies in med tech, digital health and therapeutics across Europe and North America. Gilde's portfolio companies include digital pathology image analysis company Definiens, portable oxygen concentrator player Inovalabs and neuromodulation startup Sapiens, which is focused on deep brain stimulation for Parkison's disease patients. Other fund investors included fund-of-funds, sovereign funds such as Danish Growth Fund, endowments, family offices, entrepreneurs and Gilde partners. The European Investment Fund also participated. More

> The U.S. Supreme Court ruled that federal judges should have more discretion to hand out enhanced damages in patent infringement cases. It ordered a lower appeals court to review whether Zimmer Biomet ($ZBH) wilfully violated Stryker's ($SYK) patents on a surgical cleaning wand. Story

> WuXi Hodgen Technology will invest ¥200 million ($1.9 million) in an unnamed Tokyo-based medical devices company and hold a 33% stake in the company. Release

> An NIH-funded study found that diabetics who underwent intensive glycemic control cut their risk of diabetic retinopathy in half. Release